Article summary
The European Commission has authorised the mRNA vaccine ‘mResvia’ to protect adults over 60 against lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection. This approval is the first vaccine to be authorised using mRNA technology to prevent a disease other than coronavirus (COVID-19). The European Medicines Agency authorisation comes ahead of the autumn/winter season when RSV infections tend to peak. National authorities will now decide on the vaccine’s use according to their vaccination plans.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial